Issue Information ‐ TOC
Issue Information ‐ JEB
Issue Information ‐ Jnl info
Immunotherapy in urological malignancies
Some prostate cancers are invisible to magnetic resonance imaging!
Cutaneous ureterostomy
Managing expectations after radical prostatectomy; time to change
HOXB13 mutations and prostate cancer risk
Immune checkpoint blockade – a treatment for urological cancers?
No evidence (yet) to support the statement ‘lower urinary tract symptoms (LUTS) – an independent risk factor for cardiovascular disease (CVD)’
Validation of the novel International Society of Urological Pathology 2014 five‐tier Gleason grade grouping
Recent advances in immuno‐oncology and its application to urological cancers
Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12‐core biopsy results
Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy
In‐parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance
Variation in serum prostate‐specific antigen levels in men with prostate cancer managed with active surveillance
Population‐based assessment of cancer‐specific mortality after local tumour ablation or observation for kidney cancer
Trends in stage‐specific incidence of prostate cancer in Norway, 1980–2010
Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells
Comparison of oncological and health‐related quality of life outcomes between open and robot‐assisted radical prostatectomy for localised prostate cancer – findings from the population‐based Victorian Prostate Cancer Registry
Validation of a bone scan positivity risk table in non‐metastatic castration‐resistant prostate cancer
MicroRNA‐30a as a prognostic factor in urothelial carcinoma of bladder inhibits cellular malignancy by antagonising Notch1
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration‐resistant prostate cancer
Plasma fibrinogen level
Robot‐assisted Fallopian tube transection and anastomosis using the new REVO‐I robotic surgical system
A retrospective analysis of laparoscopic partial nephrectomy with segmental renal artery clamping and factors that predict postoperative renal function
Biochemical composition of urolithiasis from stone dust – a matched‐pair analysis
Outcomes of single‐ vs double‐cuff artificial urinary sphincter insertion in low‐ and high‐risk profile male patients with severe stress urinary incontinence
Assessment of energy density usage during 180W lithium triborate laser photoselective vaporization of the prostate for benign prostatic hyperplasia. Is there an optimum amount of kilo‐Joules per gram of prostate?
A survey of patient expectations regarding sexual function following radical prostatectomy
Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness
Attitudes and knowledge of urethral catheters